Vatreptacog alfa: Phase IIIa started

Novo Nordisk disclosed in its 1H11 earnings that in July it began a double-blind, international Phase IIIa trial to compare vatreptacog alfa vs. NovoSeven in 60 patients. Novo Nordisk markets NovoSev...